Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Diabetic nephropathy (DN) / diabetic kidney disease & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

RAAS blockers have remained the mainstay of therapy for DM nephropathy for many years, with only recent advancements with SGLT2 inhibitors and nonsteroidal MRAs
Kim et al. 2022a Expert Opinion on Emerging Drugs 27(4): 417-430…

References (Sources)

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Warren et al. 2019 Expert Opin.Ther.Targ. 23: 579-591
Review
Emerging drugs for the treatment of diabetic nephropathy
Kim et al. 2022a Expert Opinion on Emerging Drugs 27(4): 417-430
Review
Novel therapeutic agents for the treatment of diabetic kidney disease
Hartman et al. 2020 Expert Opinion on Investigational Drugs 29: 1277-1293
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Diabetic nephropathy (DN) / diabetic kidney disease & Drugs/Treatments

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat